Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07300956 · ClinicalTrials.gov registry record · Phase 4
Treating Young Children With Attention Deficit Hyperactivity Disorder
A Phase 4 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Not yet
- Registry status
- Phase 4
- Development phase
- 370
- Enrollment target
NCT07300956: Clinical Trial Phase 4 study, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT07300956 is a Phase 4 study that has not yet begun recruiting, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 370 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07300956, a Phase 4 study, has not yet begun recruiting, sponsored by Children's Hospital Medical Center, Cincinnati.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 370 participants
- Enrollment target
Study Summary
This project will evaluate the effectiveness of Methylphenidate versus Guanfacine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 3 through 5 years (inclusive), as measured by clinician rating of global improvement.
Primary Outcome
The Clinical Global Impression-Improvement scale is a seven-point rating tool that evaluates how a participant's Attention-Deficit/Hyperactivity Disorder symptoms have changed since their baseline measurement. Although this scale can be used for other mental health conditions, in this study it is applied specifically to Attention-Deficit/Hyperactivity Disorder. A score of "1" indicates "very much improved," while a score of "7" indicates "very much worse." Higher scores reflect a worse outcome.
Interventions
- DRUG Methylphenidate (MPH)
- DRUG Guanfacine (GUA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2026-02 |
| Est. Completion | 2030-07 |
| Phase | Phase 4 |
What is known before NCT07300956 opens enrollment
NCT07300956 is an interventional study that assigns participants to a tested intervention. The registered 370 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 2 interventions - of which Methylphenidate (MPH) is the first listed.
NCT07300956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07300956 about?
NCT07300956 is a clinical study titled "Treating Young Children With Attention Deficit Hyperactivity Disorder". This project will evaluate the effectiveness of Methylphenidate versus Guanfacine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 3 through 5 years (inclusive), as measured by clinician rating of global improvement.
What is the current status of trial NCT07300956?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 370 participants. The study started on 2026-02. Estimated completion is 2030-07.
What interventions are being tested in trial NCT07300956?
The interventions under investigation include: Methylphenidate (MPH) (DRUG), Guanfacine (GUA) (DRUG).
Who is sponsoring clinical trial NCT07300956?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07300956's enrollment target sits among peer trials
370 223rd of 2000 higher than 1,777 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- NCT04284436 · 370 participants · NA
Study in Parkinson Disease of Exercise
- NCT05026749 · 370 participants · Phase 3
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
- NCT05125016 · 370 participants · Phase 1
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia